Simulation of clinical drug-drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs

Drug Metabolism and Disposition

Volumn 39, Issue 7, 2011, Pages 1139-1148

  Xu, Yang ^a   Zhou, Yihong ^a   Hayashi, Mike ^a   Shou, Magang ^a   Skiles, Gary L ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CYTOCHROME P450 3A4; MIDAZOLAM; NIFEDIPINE; PHENOBARBITAL; RIFAMPICIN; SIMVASTATIN; ZOLPIDEM;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG RESEARCH; ENZYME INDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; MAXIMUM PLASMA CONCENTRATION; METHODOLOGY; OPTIMAL DRUG DOSE; PHARMACODYNAMICS; PREDICTION; PRIORITY JOURNAL; SIMULATION; SIMULATOR; TREATMENT DURATION;

AREA UNDER CURVE; CARBAMAZEPINE; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ENZYME INDUCTION; HEPATOCYTES; HUMANS; MIDAZOLAM; NIFEDIPINE; PHENOBARBITAL; RIFAMPIN; SIMVASTATIN; SUBSTRATE SPECIFICITY;

EID: 79959385329     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.038067     Document Type: Article

References (70)

1. Adams M, Pieniaszek HJ Jr, Gammaitoni AR, and Ahdieh H (2005) Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways. J Clin Pharmacol 45:337-345. (Pubitemid 40490430)
2. Almond LM, Yang J, Jamei M, Tucker GT, and Rostami-Hodjegan A (2009) Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction. Curr Drug Metab 10:420-432.
3. Back DJ, Breckenridge AM, Crawford F, MacIver M, Orme ML, Park BK, Rowe PH, and Smith E (1979) The effect of rifampicin on norethisterone pharmacokinetics. Eur J Clin Pharmacol 15:193-197. (Pubitemid 9235735)
4. Back DJ, Breckenridge AM, Crawford FE, Hall JM, MacIver M, Orme ML, Rowe PH, Smith E, and Watts MJ (1980) The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women. Contraception 21:135-143. (Pubitemid 10112996)
5. Backman JT, Kivistö KT, Olkkola KT, and Neuvonen PJ (1998) The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol 54:53-58. (Pubitemid 28189400)
6. Backman JT, Kyrklund C, Kivistö KT, Wang JS, and Neuvonen PJ (2000) Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 68:122-129. (Pubitemid 30659167)
7. Backman JT, Kyrklund C, Neuvonen M, and Neuvonen PJ (2002) Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 72:685-691. (Pubitemid 36021007)
8. Backman JT, Olkkola KT, Aranko K, Himberg JJ, and Neuvonen PJ (1994) Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 37:221-225. (Pubitemid 24212179)
9. Backman JT, Olkkola KT, and Neuvonen PJ (1996) Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 59:7-13. (Pubitemid 26046768)
10. Borin MT, Chambers JH, Carel BJ, Gagnon S, and Freimuth WW (1997) Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Clin Pharmacol Ther 61:544-553.
11. Chu V, Einolf HJ, Evers R, Kumar G, Moore D, Ripp S, Silva J, Sinha V, Sinz M, and Skerjanec A (2009) In vitro and in vivo induction of cytochrome P450: a survey of the current practices and recommendations: a Pharmaceutical Research and Manufacturers of America perspective. Drug Metab Dispos 37:1339-1354.
12. Chung E, Nafziger AN, Kazierad DJ, and Bertino JS Jr (2006) Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Clin Pharmacol Ther 79:350-361.
13. Drusano GL, Townsend RJ, Walsh TJ, Forrest A, Antal EJ, and Standiford HC (1986) Steadystate serum pharmacokinetics of novobiocin and rifampin alone and in combination. Antimicrob Agents Chemother 30:42-45. (Pubitemid 16097371)
14. Eap CB, Buclin T, Cucchia G, Zullino D, Hustert E, Bleiber G, Golay KP, Aubert AC, Baumann P, Telenti A, et al. (2004) Oral administration of a low dose of midazolam (75 μg) as an in vivo probe for CYP3A activity. Eur J Clin Pharmacol 60:237-246. (Pubitemid 38916442)
15. Einolf HJ (2007) Comparison of different approaches to predict metabolic drug-drug interactions. Xenobiotica 37:1257-1294.
16. Fahmi OA, Hurst S, Plowchalk D, Cook J, Guo F, Youdim K, Dickins M, Phipps A, Darekar A, Hyland R, et al. (2009) Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction. Drug Metab Dispos 37:1658-1666.
17. Fahmi OA, Maurer TS, Kish M, Cardenas E, Boldt S, and Nettleton D (2008) A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab Dispos 36:1698-1708.
18. Floyd MD, Gervasini G, Masica AL, Mayo G, George AL Jr, Bhat K, Kim RB, and Wilkinson GR (2003) Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 13:595-606. (Pubitemid 37311146)
19. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, and Benet LZ (1995) The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 58:15-19.
20. Goodwin B, Hodgson E, and Liddle C (1999) The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol 56:1329-1339.
21. Gorski JC, Vannaprasaht S, Hamman MA, Ambrosius WT, Bruce MA, Haehner-Daniels B, and Hall SD (2003) The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity [published erratum appears in Clin Pharmacol Ther 75:249, 2004]. Clin Pharmacol Ther 74:275-287.
22. Gurley B, Hubbard MA, Williams DK, Thaden J, Tong Y, Gentry WB, Breen P, Carrier DJ, and Cheboyina S (2006) Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J Clin Pharmacol 46:201-213. (Pubitemid 43149297)
23. Gurley BJ, Swain A, Hubbard MA, Hartsfield F, Thaden J, Williams DK, Gentry WB, and Tong Y (2008) Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. Clin Pharmacol Ther 83:61-69.
24. Hebert MF, Roberts JP, Prueksaritanont T, and Benet LZ (1992) Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 52:453-457.
25. Hewitt NJ, Lechón MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, et al. (2007) Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 39:159-234.
26. Holtbecker N, Fromm MF, Kroemer HK, Ohnhaus EE, and Heidemann H (1996) The nifedipinerifampin interaction. Evidence for induction of gut wall metabolism. Drug Metab Dispos 24:1121-1123. (Pubitemid 26346226)
27. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, and Cantilena LR (1993) Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences [published erratum appears in JAMA 269:2088, 1993]. JAMA 269:1513-1518.
28. Jamei M, Dickinson GL, and Rostami-Hodjegan A (2009) A framework for assessing interindividual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of 'bottom-up' vs 'top-down' recognition of covariates. Drug Metab Pharmacokinet 24:53-75.
29. Jones SA, Moore LB, Shenk JL, Wisely GB, Hamilton GA, McKee DD, Tomkinson NC, LeCluyse EL, Lambert MH, Willson TM, et al. (2000) The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol Endocrinol 14:27-39. (Pubitemid 32260325)
30. Kajosaari LI, Laitila J, Neuvonen PJ, and Backman JT (2005) Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic Clin Pharmacol Toxicol 97:249-256. (Pubitemid 41433700)
31. Kanebratt KP and Andersson TB (2008) HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug Metab Dispos 36:137-145.
32. Kato M, Chiba K, Horikawa M, and Sugiyama Y (2005) The quantitative prediction of in vivo enzyme-induction caused by drug exposure from in vitro information on human hepatocytes. Drug Metab Pharmacokinet 20:236-243.
33. Kharasch ED, Walker A, Hoffer C, and Sheffels P (2004) Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. Clin Pharmacol Ther 76:452-466. (Pubitemid 39469869)
34. Kozawa M, Honma M, and Suzuki H (2009) Quantitative prediction of in vivo profiles of CYP3A4 induction in humans from in vitro results with a reporter gene assay. Drug Metab Dispos 37:1234-1241.
35. Lang CC, Jamal SK, Mohamed Z, Mustafa MR, Mustafa AM, and Lee TC (2003) Evidence of an interaction between nifedipine and nafcillin in humans. Br J Clin Pharmacol 55:588-590. (Pubitemid 36783200)
36. LeCluyse E, Madan A, Hamilton G, Carroll K, DeHaan R, and Parkinson A (2000) Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes. J Biochem Mol Toxicol 14:177-188.
37. Lin JH (2006) CYP induction-mediated drug interactions: in vitro assessment and clinical implications. Pharm Res 23:1089-1116.
38. Lin JH and Lu AY (1998) Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35:361-390. (Pubitemid 28520008)
39. Link B, Haschke M, Grignaschi N, Bodmer M, Aschmann YZ, Wenk M, and Krähenbühl S (2008) Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping. Br J Clin Pharmacol 66:473-484.
40. Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, Downey AD, Czerwinski M, Forster J, Ribadeneira MD, et al. (2003) Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 31:421-431. (Pubitemid 36378519)
41. Mills JB, Rose KA, Sadagopan N, Sahi J, and de Morais SM (2004) Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line. J Pharmacol Exp Ther 309:303-309. (Pubitemid 38393143)
42. Modry DL, Stinson EB, Oyer PE, Jamieson SW, Baldwin JC, and Shumway NE (1985) Acute rejection and massive cyclosporine requirements in heart transplant recipients treated with rifampin. Transplantation 39:313-314. (Pubitemid 15137832)
43. Moore JT and Kliewer SA (2000) Use of the nuclear receptor PXR to predict drug interactions. Toxicology 153:1-10.
44. Nair DR and Morris HH (1999) Potential fluconazole-induced carbamazepine toxicity. Ann Pharmacother 33:790-792. (Pubitemid 29387655)
45. Ndanusa BU, Mustapha A, and Abdu-Aguye I (1997) The effect of single dose of rifampicin on the pharmacokinetics of oral nifedipine. J Pharm Biomed Anal 15:1571-1575. (Pubitemid 27268336)
46. Ohnhaus EE, Brockmeyer N, Dylewicz P, and Habicht H (1987) The effect of antipyrine and rifampin on the metabolism of diazepam. Clin Pharmacol Ther 42:148-156. (Pubitemid 17135970)
47. Pelkonen O, Myllynen P, Taavitsainen P, Boobis AR, Watts P, Lake BG, Price RJ, Renwick AB, Gómez-Lechón MJ, Castell JV, et al. (2001) Carbamazepine: a 'blind' assessment of CVP-associated metabolism and interactions in human liver-derived in vitro systems. Xenobiotica 31:321-343. (Pubitemid 32679311)
48. Rae JM, Johnson MD, Lippman ME, and Flockhart DA (2001) Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 299:849-857. (Pubitemid 33104951)
49. Rapeport WG, Williams SA, Muirhead DC, Dewland PM, Tanner T, and Wesnes K (1996) Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. J Clin Psychiatry 57 (Suppl 1):20-23. (Pubitemid 26144854)
50. Reidenberg P, Glue P, Banfield CR, Colucci RD, Meehan JW, Radwanski E, Mojavarian P, Lin CC, Nezamis J, and Guillaume M (1995) Effects of felbamate on the pharmacokinetics of phenobarbital. Clin Pharmacol Ther 58:279-287.
51. Ripp SL, Mills JB, Fahmi OA, Trevena KA, Liras JL, Maurer TS, and de Morais SM (2006) Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. Drug Metab Dispos 34:1742-1748. (Pubitemid 44427477)
52. Rostami-Hodjegan A and Tucker GT (2007) Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6:140-148. (Pubitemid 46745341)
53. Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, and Olkkola KT (2007) Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects. Br J Clin Pharmacol 63:116-120. (Pubitemid 44902885)
54. Schellens JH, van der Wart JH, Brugman M, and Breimer DD (1989) Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design. J Pharmacol Exp Ther 249:638-645.
55. Shou M, Hayashi M, Pan Y, Xu Y, Morrissey K, Xu L, and Skiles GL (2008) Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction. Drug Metab Dispos 36:2355-2370.
56. Swaisland HC, Ranson M, Smith RP, Leadbetter J, Laight A, McKillop D, and Wild MJ (2005) Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet 44:1067-1081. (Pubitemid 41356392)
57. Thummel KE, Shen DD, Isoherranen N, and Smith HE (2006) Design and optimization of dosage regimens; pharmacokinetic data, in Goodman & Gilman's the Pharmacological Basis of Therapeutics, 11th ed (Brunton LL, Lazo J, and Parker K eds) pp 1787-1888, McGraw-Hill, Chicago.
58. Tirona RG, Leake BF, Wolkoff AW, and Kim RB (2003) Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 304:223-228. (Pubitemid 36008932)
59. Ucar M, Neuvonen M, Luurila H, Dahlqvist R, Neuvonen PJ, and Mjörndal T (2004) Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. Eur J Clin Pharmacol 59:879-882. (Pubitemid 38333678)
60. Uchida S, Yamada H, Li XD, Maruyama S, Ohmori Y, Oki T, Watanabe H, Umegaki K, Ohashi K, and Yamada S (2006) Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J Clin Pharmacol 46:1290-1298. (Pubitemid 44564357)
61. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, and Fattinger K (2002) Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36:164-172. (Pubitemid 34700774)
62. Villikka K, Kivistö KT, Luurila H, and Neuvonen PJ (1997) Rifampin reduces plasma concentrations and effects of zolpidem. Clin Pharmacol Ther 62:629-634. (Pubitemid 28068066)
63. Von Moltke LL, Greenblatt DJ, Granda BW, Duan SX, Grassi JM, Venkatakrishnan K, Harmatz JS, and Shader RI (1999) Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations. Br J Clin Pharmacol 48:89-97. (Pubitemid 29296668)
64. Wang YH (2010) Confidence assessment of the Simcyp time-based approach and a static mathematical model in predicting clinical drug-drug interactions for mechanism-based CYP3A inhibitors. Drug Metab Dispos 38:1094-1104.
65. Xu L, Chen Y, Pan Y, Skiles GL, and Shou M (2009) Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator. Drug Metab Dispos 37:2330-2339.
66. Yang J, Jamei M, Heydari A, Yeo KR, de la Torre R, Farré M, Tucker GT, and Rostami-Hodjegan A (2006) Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. J Psychopharmacol 20:842-849. (Pubitemid 44622750)
67. Yang J, Jamei M, Yeo KR, Tucker GT, and Rostami-Hodjegan A (2007) Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 8:676-684. (Pubitemid 47578116)
68. Yang J, Liao M, Shou M, Jamei M, Yeo KR, Tucker GT, and Rostami-Hodjegan A (2008) Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr Drug Metab 9:384-394.
69. Yao C and Levy RH (2002) Inhibition-based metabolic drug-drug interactions: predictions from in vitro data. J Pharm Sci 91:1923-1935. (Pubitemid 36254929)
70. Zhao P, Ragueneau-Majlessi I, Zhang L, Strong JM, Reynolds KS, Levy RH, Thummel KE, and Huang SM (2009) Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study. J Clin Pharmacol 49:351-359.